Literature DB >> 9826206

Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia.

J D Sparks1, T L Phung, M Bolognino, J Cianci, R Khurana, R G Peterson, M P Sowden, J P Corsetti, C E Sparks.   

Abstract

Lipoprotein and apolipoprotein parameters were studied in the male Zucker diabetic fatty (ZDF) rat at 10 and 20 weeks of age, corresponding to hyperinsulinemic and insulinopenic type 2 diabetes mellitus, respectively. At both ages, ZDF rats had elevated serum triglycerides, free fatty acids, and corticosterone, whereas 20-week ZDF rats had reduced thyroid hormones. At 10 weeks, the hyperlipidemia was confined to elevations in pre-beta triglyceride-rich (d < 1.006 g/mL) lipoproteins. By 20 weeks, all lipoprotein density fractions were increased compared with lean rats, with substantial increases in both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol. In ZDF rats, there was a progressive increase in apolipoprotein B (apo B) from 1.9 times control at 10 weeks to three times control at 20 weeks. The increase in apo B was accompanied by a shift of apo B, particularly B100, from very-low-density lipoprotein (VLDL) into denser lipoproteins corresponding to intermediate-density lipoproteins plus LDLs (1.006 < d < 1.063 g/mL). In Zucker and 10-week ZDF rats, in the presence of hyperinsulinemia, the increase in serum apo B was predominantly apo B48 present in VLDL. By 20 weeks, when ZDF rats are insulinopenic, the mass ratio of B48:B100 shifted from 2.7 to 0.7. The shift was associated with a decrease in hepatic-edited apo B mRNA. Apo E increased in lean rats between 10 and 20 weeks of age. Although apo E also increased in ZDF rats, the increase by 20 weeks was less than that of lean rats. The molar ratio of apo E to B in VLDL was decreased in ZDF rats. In lean rats, greater than 50% of apo E was present in HDL, in contrast to ZDF rats, where less than 20% of apo E was present in HDL. VLDL apo E shifted to denser fractions by 20 weeks of age, similar to apo B. The apo C level was more than double compared with the level in lean rats and was redistributed from the HDL fraction to lipoprotein fractions containing apo B. Both apo A-I and apo A-IV levels more than doubled between 10 and 20 weeks in ZDF rats. The ZDF rat model may be useful in comparative studies of lipoproteins during diabetic progression from hyperinsulinemia to insulinopenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826206     DOI: 10.1016/s0026-0495(98)90298-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats.

Authors:  Min Lu; David Patsouris; Pingping Li; Jaime Flores-Riveros; James M Frincke; Steve Watkins; Simon Schenk; Jerrold M Olefsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

2.  Phosphatidylinositol (3,4,5)-trisphosphate binds to sortilin and competes with neurotensin: Implications for very low density lipoprotein binding.

Authors:  Robert P Sparks; Jermaine L Jenkins; Gregory E Miner; Yan Wang; Wayne C Guida; Charles E Sparks; Rutilio A Fratti; Janet D Sparks
Journal:  Biochem Biophys Res Commun       Date:  2016-09-22       Impact factor: 3.575

3.  An Allosteric Binding Site on Sortilin Regulates the Trafficking of VLDL, PCSK9, and LDLR in Hepatocytes.

Authors:  Robert P Sparks; Andres S Arango; Jermaine L Jenkins; Wayne C Guida; Emad Tajkhorshid; Charles E Sparks; Janet D Sparks; Rutilio A Fratti
Journal:  Biochemistry       Date:  2020-11-05       Impact factor: 3.162

4.  Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension.

Authors:  Lisa A Lesniewski; Anthony J Donato; Bradley J Behnke; Christopher R Woodman; M Harold Laughlin; Chester A Ray; Michael D Delp
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-01       Impact factor: 4.733

Review 5.  Rodent models for metabolic syndrome research.

Authors:  Sunil K Panchal; Lindsay Brown
Journal:  J Biomed Biotechnol       Date:  2010-12-30

Review 6.  Updating experimental models of diabetic cardiomyopathy.

Authors:  J Fuentes-Antrás; B Picatoste; A Gómez-Hernández; J Egido; J Tuñón; Ó Lorenzo
Journal:  J Diabetes Res       Date:  2015-04-20       Impact factor: 4.011

7.  Histological Evaluation of Diabetic Neurodegeneration in the Retina of Zucker Diabetic Fatty (ZDF) Rats.

Authors:  Klaudia Szabó; Anna Énzsöly; Bulcsú Dékány; Arnold Szabó; Rozina I Hajdú; Tamás Radovits; Csaba Mátyás; Attila Oláh; Lenke K Laurik; Gábor M Somfai; Béla Merkely; Ágoston Szél; Ákos Lukáts
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats.

Authors:  Eduardo J Lezcano; Pablo Iñigo; Ana M Larraga; Cristina Barranquero; Ignacio Gimenez; Jesús Osada
Journal:  Diabetol Metab Syndr       Date:  2014-01-27       Impact factor: 3.320

Review 9.  Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes.

Authors:  Bingxuan Wang; P Charukeshi Chandrasekera; John J Pippin
Journal:  Curr Diabetes Rev       Date:  2014-03

10.  Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?

Authors:  Maria-Cristina Porfirio; Juliana Paula Gomes de Almeida; Maddalena Stornelli; Silvia Giovinazzo; Diane Purper-Ouakil; Gabriele Masi
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-10       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.